People
Autolus Names Linda Bain to Board of Directors
12 June 2018 - - London, England-based privately held biopharmaceutical company Autolus will appoint Linda Bain to the Autolus board of directors, effective prior to the closing of Autolus' planned initial public offering, the company said.
Bain is a certified public accountant with over 20 years of finance and audit experience in the biotech and pharmaceutical industry.
Currently, she serves as chief financial officer of Codiak BioSciences, a privately held company in the emerging field of exosome therapeutics.
She received her B.S in Accounting and Business Administration and an Honors Degree in Accounting and Business Administration from the University of the Free State, South Africa.
Autolus is developing next-generation, programmed T cell therapies for the treatment of cancer.
Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells.
Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours.
Login
Username:

Password: